This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ritalin

Novartis AG

Drug Names(s): methylphenidate hydrochloride

Description: Ritalin hydrochloride is a central nervous system stimulant. The exact mechanism of action in ADHD is unknown. The drug is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. In this way, ritalin hydrochloride presumably activates the brain stem arousal system and cortex to produce its stimulant effect.

Deal Structure: Celgene entered into an agreement with Novartis in April 2000 and receives royalties on all of Novartis' Ritalin family of ADHD-related products.

Partners: Celgene Corporation


Ritalin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug